Durect Corp DRRX

NAS: DRRX | ISIN: US2666051048   30/04/2025
0,600 USD (-3,24%)
(-3,24%)   30/04/2025

26 maart 2025 · DURECT Corporation Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update · Persbericht

19 maart 2025 · DURECT Corporation to Announce Fourth Quarter and Full Year 2024 Financial Results and Provide a Business Update · Persbericht

4 september 2024 · DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference · Persbericht

13 augustus 2024 · DURECT Corporation Reports Second Quarter 2024 Financial Results and Business Update · Persbericht

7 augustus 2024 · DURECT Corporation to Announce Second Quarter 2024 Financial Results and Provide a Business Update · Persbericht

21 mei 2024 · DURECT Corporation Receives FDA Breakthrough Therapy Designation for Larsucosterol in Alcohol-Associated Hepatitis · Persbericht

13 mei 2024 · DURECT Corporation Reports First Quarter 2024 Financial Results and Business Update · Persbericht

7 mei 2024 · DURECT Corporation to Announce First Quarter 2024 Financial Results and Provide a Business Update · Persbericht

30 april 2024 · DURECT Corporation Announces Late-Breaking Oral Presentation at the EASL Congress 2024 to Discuss AHFIRM Phase 2b Data in Alcohol-Associated Hepatitis · Persbericht

27 maart 2024 · DURECT Corporation Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update · Persbericht

20 maart 2024 · DURECT Corporation to Announce Fourth Quarter and Full Year 2023 Financial Results and Provide a Business Update · Persbericht

4 maart 2024 · DURECT and Charles River Laboratories Enter into Co-Marketing and Collaboration Agreement for ALZET® Product Line in U.S. and Canada · Persbericht

8 februari 2024 · DURECT Corporation to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference · Persbericht

9 november 2023 · DURECT Corporation to Announce Third Quarter 2023 Financial Results and Provide a Business Update · Persbericht

7 november 2023 · DURECT Corporation Announces Topline Results from Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis with Promising Effect on Mortality · Persbericht

7 september 2023 · DURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated Hepatitis · Persbericht

31 augustus 2023 · DURECT Corporation Announces Presentations in Upcoming Investor Conferences · Persbericht

9 augustus 2023 · DURECT Corporation Reports Second Quarter 2023 Financial Results and Business Update · Persbericht

3 augustus 2023 · DURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business Update · Persbericht

20 juli 2023 · DURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules · Persbericht

Mijn selecties